美国杜克大学Xiling Shen和David Hsu研究团队合作的最新研究的研究显示，患者来源的微器官球为临床精准靶肿瘤提供了可能。2022年5月3日，国际学术期刊《细胞-干细胞》发表了这一成果。

研究人员使用具有温度控制和死体积最小化的液滴乳液微流体，从患者低容量组织中快速生成数千个微有机球 (MOS)，这是临床精准肿瘤治疗的理想衍生模型。对最近诊断出转移性结直肠癌(CRC)患者的临床研究表明，使用基于MOS的精准肿瘤学策略可在14天内准确评估肿瘤药物反应，该时间表适用于临床治疗决策的确立。

此外，MOS捕获原始基质细胞并允许T细胞渗透，为测试肿瘤免疫(IO)疗法（例如PD-1阻断、双特异性抗体和T细胞疗法对患者肿瘤的反应）提供了临床试验可能。

据悉，已有研究表明患者来源的异种移植物(PDX)和患者来源的类器官(PDO)可用于模拟癌症治疗的临床反应。然而，使用这些模型来确定癌症患者的临床治疗策略仍然具有挑战性。

附：英文原文

Title: Patient-derived micro-organospheres enable clinical precision oncology

Author: Shengli Ding, Carolyn Hsu, Zhaohui Wang, Naveen R. Natesh, Rosemary Millen, Marcos Negrete, Nicholas Giroux, Grecia O. Rivera, Anders Dohlman, Shree Bose, Tomer Rotstein, Kassandra Spiller, Athena Yeung, Zhiguo Sun, Chongming Jiang, Rui Xi, Benjamin Wilkin, Peggy M. Randon, Ian Williamson, Daniel A. Nelson, Daniel Delubac, Sehwa Oh, Gabrielle Rupprecht, James Isaacs, Jingquan Jia, Chao Chen, John Paul Shen, Scott Kopetz, Shannon McCall, Amber Smith, Nikolche Gjorevski, Antje-Christine Walz, Scott Antonia, Estelle Marrer-Berger, Hans Clevers, David Hsu, Xiling Shen

Issue&Volume: 2022-05-03

Abstract: Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shownto model clinical response to cancer therapy. However, it remains challenging to usethese models to guide timely clinical decisions for cancer patients. Here, we useddroplet emulsion microfluidics with temperature control and dead-volume minimizationto rapidly generate thousands of micro-organospheres (MOSs) from low-volume patienttissues, which serve as an ideal patient-derived model for clinical precision oncology.A clinical study of recently diagnosed metastatic colorectal cancer (CRC) patientsusing an MOS-based precision oncology pipeline reliably assessed tumor drug responsewithin 14 days, a timeline suitable for guiding treatment decisions in the clinic.Furthermore, MOSs capture original stromal cells and allow T cell penetration, providinga clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade,bispecific antibodies, and T cell therapies on patient tumors.

DOI: 10.1016/j.stem.2022.04.006

Source: https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(22)00159-X